14 results about "Increased hdl" patented technology

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The invention relates to the technical field of functional food, in particular to a tartary buckwheat and roxburgh rose composition for regulating blood pressure and blood fat and a preparation method thereof. The tartary buckwheat and roxburgh rose composition comprises tartary buckwheat and roxburgh rose. The mass ratio of the tartary buckwheat to the roxburgh rose is 1: (1-3). In-vitro activity evaluation, cell experiments and animal experiments prove that flavonoid compounds of tartary buckwheat and active ingredients such as vitamin C of roxburgh rose in the composition generate a synergistic effect, so that the antioxidant capacity, the ACE inhibition rate, the cholesterol clearance rate and the pancreatic lipase inhibition rate can be remarkably improved, NO generation is effectively promoted, and the curative effect is good. The contents of TC, TG and LDL-L are reduced, the HDL-L level is increased, and the balance of vascular active substances is regulated. The raw materials are all medicinal and edible, are high in safety and free of side effects, provide a natural and efficient auxiliary conditioning scheme for chronic metabolic diseases such as hypertension and hyperlipidemia, and have a good industrialization prospect.

This invention relates to methods and compositions useful in subjects suffering from or at risk of suffering from sepsis or other dysregulated inflammatory responses. It has been demonstrated that the CETP inhibitor obicetrapib not only preserved or increased HDL-C and Apo A1 levels, but also reduced an important pro-inflammatory marker, IL-1β, and significantly increased survival, relative to placebo, in a suitable sepsis mouse model. Thus, broadly stated, the present invention concerns the use of CETP inhibitors in the prevention, treatment, management or amelioration of sepsis, or other dysregulated inflammatory responses in a subject.

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and / or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

The application discloses a polysaccharide composition for treating hyperlipidemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing Vansant yellow, Inonotus hispidus and Sarcodon fuligineus and then extracting with water. The polysaccharide composition can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide, thereby providing a new direction for the treatment of auxiliary blood sugar reduction.

The invention provides a double-layer tablet containing ezetimibe and fenofibrate. The double-layer tablet comprises an ezetimibe quick release layer and a fenofibrate slow release layer, the ezetimibe quick-release layer comprises ezetimibe, a quick-release layer filler, a quick-release layer surfactant, a quick-release layer adhesive, a quick-release layer disintegrating agent and a quick-release layer lubricant; the fenofibrate sustained-release layer comprises fenofibrate, a sustained-release layer filler, a sustained-release layer disintegrating agent, a sustained-release layer adhesive, a sustained-release layer solubilizer, a sustained-release layer sustained-release framework material and a sustained-release layer lubricant. The invention also provides a preparation method of the double-layer tablet. The double-layer tablet provided by the invention can be used for clinical treatment of hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia, the levels of triglyceride, total cholesterol and LDL-C are comprehensively reduced, the level of HDL-C is increased, and the occurrence rate of adverse reactions is relatively low.

The invention relates to application of ginsenoside CK in preparation of drugs for treating diseases by activating PPAR gamma and / or CPT1A pathways, and belongs to the technical field of medicines.The action mechanism of ginsenoside CK in prevention or treatment of metabolism-related fatty liver diseases (MAFLD) is obtained for the first time through research, and by establishing an MAFLD mouse model and an MAFLD cell model respectively, the action mechanism of ginsenoside CK in prevention or treatment of metabolism-related fatty liver diseases is obtained. Through PPAR gamma and CPT1A inhibition and ginsenoside CK intervention tests, the application of ginsenoside CK in remarkably reducing expression of ACC1 / FAS / SREBP1c, improving expression of CPT1 / CPT2, reducing serum TG / TC / FFA / LDL-C / ALT / AST level, increasing HDL-C, reducing hypoglycemia / insulin level and insulin resistance index, reducing ROS accumulation of hepatocytes, improving mitochondrial membrane potential, improving mitochondrial membrane potential, reducing liver cancer, reducing liver cancer, reducing liver cancer, reducing liver cancer, reducing liver cancer, reducing liver cancer and reducing liver cancer. The invention relates to a mechanism for preventing or treating MAFLD by inhibiting an NF-kappa B / JNK inflammation pathway and the like, and provides a new candidate component for research and development of MAFLD treatment drugs.

The invention provides application of SPPARMs in treatment of atherosclerosis, and belongs to the technical field of biological medicine. An ApoE gene knockout mouse is subjected to high-fat feeding to construct an atherosclerotic mouse model, THP-1 macrophages are exposed to oxidized low-density lipoprotein to construct a macrophage foaming model, INT131 is used for drug administration to an animal model and a cell model, and results show that INT131 can effectively relieve formation of atherosclerotic plaques, and can be used for treating atherosclerotic plaques. The content of AS mouse serum total cholesterol and low-density lipoprotein cholesterol is obviously reduced, and the content of high-density lipoprotein cholesterol is increased. In addition, INT131 can reduce intake of lipid in macrophages, promote cholesterol excretion and cholesterol metabolism, and inhibit formation of foam cells by inhibiting inflammatory response.

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

The invention discloses a composition for diabetes. The composition comprises carbohydrate, dietary fiber, protein, grease and trace elements. The composition can reduce fasting blood glucose levels, reduce serum triglyceride and total cholesterol levels, increase high density lipoprotein levels and improve insulin tolerance in diabetic patients. Therefore, the composition is used for preparing medicines or health-care products for treating and / or preventing diabetes mellitus.

The invention discloses a beta-lactoglobulin-procyanidine covalent complex as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The compound is prepared by an alkali treatment method which comprises the following steps: mixing beta-lactoglobulin and procyanidine according to a mass ratio of 5: 1, reacting for 24 hours under the conditions that the pH is 9.0 and the room temperature is dark, neutralizing, dialyzing and freeze-drying to obtain the compound. The preparation process is simple, and conditions are mild. The obtained compound has good biological safety and remarkable activity of resisting the non-alcoholic fatty liver disease, and can effectively inhibit lipid deposition of hepatocytes, reduce the total cholesterol and triglyceride level of serum of the hepatocytes and mice and improve the blood lipid spectrum (reducing LDL-c and increasing HDL-c). The traditional Chinese medicine composition is natural in raw materials and remarkable in effect, and has the potential of being developed into drugs for preventing and / or treating the non-alcoholic fatty liver disease and related lipid metabolism disorders.

The invention discloses a blood fat reducing composition containing supramolecular group composite peptide, which is composed of raw materials and basic energy substrates, the raw materials comprise supramolecular group composite peptide, natto freeze-dried powder, black pepper extract and bamboo leaf flavone, and the basic energy substrates comprise proteins, dietary fibers, fatty acids and / or lipids; the composite peptide is composed of soybean peptide and bitter gourd peptide. The composition prepared by compounding the components of specific types and dosages has the effects of remarkably reducing the triglyceride level, reducing the content of low-density lipoprotein cholesterol and increasing the content of high-density lipoprotein cholesterol, and part of the composition can also cooperate with statin western medicines (such as atorvastatin calcium) to achieve the effects of enhancing the effect of reducing blood fat and improving the blood fat content. The effect of assisting in improving or preventing and reducing blood fat is achieved. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The present invention pertains to manufacturing processes for producing dried coffee skin and pulp (dried cascara), extract drink products, and powder products from coffee cherry skin and pulp. The processes comprise the following key methods: (i) a processing method for producing dried coffee cherry skin and pulp, (ii) a processing method for producing extract drink products from dried coffee cherry skin and pulp, and (iii) a processing method for producing powder products from dried coffee cherry skin and pulp. The resultant products have been clinically demonstrated to lower LDL, triglycerides, and total cholesterol levels while increasing HDL levels. Moreover, they significantly reduce insulin resistance and inflammatory conditions in the body. Accordingly, these products serve as novel alternative food supplements suitable for health-conscious individuals and those with hyperlipidemia.